Skip to main content
×
×
Home

Cost-effectiveness of targeted screening for hepatitis C in The Netherlands

  • C. W. HELSPER (a1), B. A. BORKENT-RAVEN (a1), N. J. DE WIT (a1), G. A. VAN ESSEN (a1), M. J. M. BONTEN (a1) (a2), A. I. M. HOEPELMAN (a2), M. P. JANSSEN (a1) and G. A. DE WIT (a1) (a3)...
Summary

On account of the serious complications of hepatitis C virus (HCV) infection and the improved treatment possibilities, the need to improve HCV awareness and case-finding is increasingly recognized. To optimize a future national campaign with this objective, three pilot campaigns were executed in three regions in The Netherlands. One campaign was aimed at the general population, a second (similar) campaign was extended with a support programme for primary care and a third campaign was specifically aimed at hard-drug users. Data from the pilot campaigns were used to build a mathematical model to estimate the incremental cost-effectiveness ratio of the different campaigns. The campaign aimed at the general public without support for primary care did not improve case-finding and was therefore not cost-effective. The similar campaign accompanied by additional support for primary care and the campaign aimed at hard-drug users emerged as cost-effective interventions for identification of HCV carriers.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cost-effectiveness of targeted screening for hepatitis C in The Netherlands
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cost-effectiveness of targeted screening for hepatitis C in The Netherlands
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cost-effectiveness of targeted screening for hepatitis C in The Netherlands
      Available formats
      ×
Copyright
Corresponding author
*Author for correspondence: C. W. Helsper, M.D., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands, PO Box 85500, 3508 GA Utrecht, The Netherlands. (Email: c.helsper@gmail.com)
References
Hide All
1.Shepard, CW, Finelli, L, Alter, MJ. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5: 558567.
2.World Health Organisation.Hepatitis C: global prevalence. Weekly Epidemiological Record 1997; 72: 341344.
3.Lauer, GM, Walker, BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 4152.
4.Manns, MP, et al. The way forward in HCV treatment-finding the right path. Nature Reviews Drug Discovery 2007; 6: 991–1000.
5.Thompson-Coon, J, et al. Case finding for hepatitis C in primary care: a cost utility analysis. Family Practice 2006; 23: 393406.
6.Foster, GR, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. British Medical Journal 1997; 315: 453458.
7.Slavenburg, S, et al. Prevalence of hepatitis C in the general population in the Netherlands. Netherlands Journal of Medicine 2008; 66: 1317.
8.Kretzschmar, MEE.The prevalence of hepatitis C in the Netherlands [in Dutch]. Bilthoven, the Netherlands, National Institute of Public Health and the Environment, 2004; publication number VWS-IGZ 2004/02 – Project V/210041.
9.Kok, A, et al. Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2007; 151: 23672371.
10.Health Council of the Netherlands. Committee on hepatitis C. Detection and treatment of people with hepatitis C. Rijswijk: Health Council of the Netherlands, 1997; publication no. 1997/19.
11.de Vries, MJ, te Rijdt, B, van Nieuwkerk, CM. Transmission of hepatitis C genotypes in the Netherlands amongst recently genotyped patients. Netherlands Journal of Medicine 2008; 66: 4041.
12.Frank, C, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887891.
13.Meltzer, MI. Introduction to health economics for physicians. Lancet 2001; 358: 993998.
14.Helsper, CW, et al. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice 2010; 27: 328332.
15.Laar van, MW, et al. National drug monitor 2007. Utrecht, The Netherlands, Trimbos Institute. WODC research and documentation centre, 2008, publication no. AF0809.
16.Veen van der, C, Hoogenboezem, G, Breemer, J. Education campaign aimed at hard drug users. Results of a pilot study [in Dutch]. Verslaving: Tijdschrift over Verslavingsproblematiek 2009; 5: 6171.
17.Siebert, U, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425432.
18.StatLine – Statistics Netherlands. (http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=60020&LA=NL) [in Dutch]. Accessed 6 October 2006.
19.Smyth, B, Fan, J, Hser, YI. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. Journal of Addictive Diseases 2006; 25: 3747.
20.Organisation for Economic Cooperation and Development (OECD). Health Data 2007 (CD-ROM), 2007.
21.Breemer, J, et al. Pre- and post-test counselling of hepatitis C, HIV and hepatitis B. Test protocol. Project active testing in addiction care and social shelter [in Dutch]. Rotterdam, The Netherlands: GGD Rotterdam-Rijnmond 2007.
22.Veldt, B.Long-term clinical outcome of treatment for chronic hepatitis C [dissertation]. Rotterdam, the Netherlands: Rotterdam University, 2008, 52 pp.
23.Rodenburg-van Dieten, H.Guidelines for farmaco-economic research [in Dutch]. Diemen, the Netherlands: College voor Zorgverzekeringen, 2006, publication number FARM 24088606.
24.Op de Coul, E, Bosman, A, van de Laar, M. Surveillance of hepatitis C in the Netherlands, 1992–2002 [in Dutch]. Infectieziekten Bulletin 2003; 9: 323328.
25.de Jong, DJ, et al. Referral of hepatitis C virus seropositive patients in primary care in the Netherlands. Netherlands Journal of Medicine 2008; 66: 4243.
26.The Health Care Insurance Board (CVZ). Farmacotherapeutic Compass database (http://www.fk.cvz.nl/). Accessed 8 July 2008.
27.Statistics Netherlands (CBS). CBS table: Population per region subdivided to country and gender Database (http://statline.cbs.nl/StatWeb/). Accessed 1 January 2006.
28.Berg van den, M, et al. Cost-effectiveness of prevention: opportunities for public health policy in the Netherlands [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2008; 152: 13291334.
29.Castelnuovo, E, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment 2006; 10: xiii–iv, ixxii, 193.
30.Stein, K, et al. Screening for hepatitis C in injecting drug users: a cost utility analysis. Journal of Public Health (Oxford) 2004; 26: 6171.
31.Sroczynski, G, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. European Journal of Public Health 2009; 19: 245253.
32.Statistics Netherlands (CBS). CBS table: Population of the Netherlands on first of January; age, country of birth and region (http://statline.cbs.nl/StatWeb/). Accessed 16 September 2009.
33.Wilson, JMG, Jungner, G. Principles and practice of mass screening for disease. Boletín de la Oficina Sanitaria Panamericana 1968; 65: 281393.
34.Andermann, A, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008; 86: 317319.
35.Veldhuijzen, IK, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522530.
36.Paltiel, AD, et al. Expanded screening for HIV in the United States – an analysis of cost-effectiveness. New England Journal of Medicine 2005; 352: 586595.
37.Bozzette, SA. Routine screening for HIV infection-timely and cost-effective. New England Journal of Medicine 2005; 352: 620621.
38.Soriano, V, Peters, MG, Zeuzem, S. New therapies for hepatitis C virus infection. Clinical Infectious Diseases 2009; 48: 313320.
39.Zeuzem, S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5: 610622.
40.Statistics Netherlands (CBS). CBS table: immigration and emigration (http://statline.cbs.nl/StatWeb/). Accessed 16 September 2009.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: -
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
WORD
Supplementary materials

Helsper Supplementary Material
Helsper Supplementary Tables

 Word (134 KB)
134 KB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed